Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 13 02 2021
accepted: 07 04 2021
pubmed: 24 8 2021
medline: 16 10 2021
entrez: 23 8 2021
Statut: ppublish

Résumé

No simple staging system has emerged for basal cell carcinomas (BCCs), since they do not follow the TNM process, and practitioners failed to agree on simple clinical or pathological criteria as a basis for a classification. Operational classification of BCCs is required for decision-making, trials and guidelines. Unsupervised clustering of real cases of difficult-to-treat BCCs (DTT-BCCs; part 1) has demonstrated that experts could blindly agree on a five groups classification of DTT-BCCs based on five patterns of clinical situations. Using this five patterns to generate an operational and comprehensive classification of BCCs. Testing practitioner's agreement, when using the five patterns classification to ensure that it is robust enough to be used in the practice. Generating the first version of a staging system of BCCs based on pattern recognition. Sixty-two physicians, including 48 practitioners and the 14 experts who participated in the generation of the five different patterns of DTT-BCCs, agreed on 90% of cases when classifying 199 DTT-BCCs cases using the five patterns classification (part 1) attesting that this classification is understandable and usable in practice. In order to cover the whole field of BCCs, these five groups of DTT-BCCs were added a group representing the huge number of easy-to-treat BCCs, for which sub-classification has little interest, and a group of very rare metastatic cases, resulting in a four-stage and seven-substage staging system of BCCs. A practical classification adapted to the specificities of BCCs is proposed. It is the first tumour classification based on pattern recognition of clinical situations, which proves to be consistent and usable. This EADO staging system version 1 will be improved step by step and tested as a decision tool and a prognostic instrument.

Sections du résumé

BACKGROUND BACKGROUND
No simple staging system has emerged for basal cell carcinomas (BCCs), since they do not follow the TNM process, and practitioners failed to agree on simple clinical or pathological criteria as a basis for a classification. Operational classification of BCCs is required for decision-making, trials and guidelines. Unsupervised clustering of real cases of difficult-to-treat BCCs (DTT-BCCs; part 1) has demonstrated that experts could blindly agree on a five groups classification of DTT-BCCs based on five patterns of clinical situations.
OBJECTIVE OBJECTIVE
Using this five patterns to generate an operational and comprehensive classification of BCCs.
METHOD METHODS
Testing practitioner's agreement, when using the five patterns classification to ensure that it is robust enough to be used in the practice. Generating the first version of a staging system of BCCs based on pattern recognition.
RESULTS RESULTS
Sixty-two physicians, including 48 practitioners and the 14 experts who participated in the generation of the five different patterns of DTT-BCCs, agreed on 90% of cases when classifying 199 DTT-BCCs cases using the five patterns classification (part 1) attesting that this classification is understandable and usable in practice. In order to cover the whole field of BCCs, these five groups of DTT-BCCs were added a group representing the huge number of easy-to-treat BCCs, for which sub-classification has little interest, and a group of very rare metastatic cases, resulting in a four-stage and seven-substage staging system of BCCs.
CONCLUSION CONCLUSIONS
A practical classification adapted to the specificities of BCCs is proposed. It is the first tumour classification based on pattern recognition of clinical situations, which proves to be consistent and usable. This EADO staging system version 1 will be improved step by step and tested as a decision tool and a prognostic instrument.

Identifiants

pubmed: 34424580
doi: 10.1111/jdv.17467
pmc: PMC8597032
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2149-2153

Subventions

Organisme : Roche
Organisme : Sun Pharma

Informations de copyright

© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Références

Eur J Dermatol. 2006 Jul-Aug;16(4):394-401
pubmed: 16935797
Eur J Dermatol. 2014 May-Jun;24(3):312-29
pubmed: 24723647
Eur J Surg Oncol. 2019 Feb;45(2):235-241
pubmed: 30385156
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):1949-1956
pubmed: 34432327
Eur J Cancer. 2019 Sep;118:10-34
pubmed: 31288208
Future Oncol. 2015;11(4):703-12
pubmed: 25686123
J Natl Compr Canc Netw. 2016 May;14(5):574-97
pubmed: 27160235
Scand J Plast Reconstr Surg Hand Surg. 1995 Jun;29(2):141-8
pubmed: 7569811
Br J Dermatol. 2008 Jul;159(1):35-48
pubmed: 18593385

Auteurs

J J Grob (JJ)

Aix-Marseille University, APHM, Marseille, France.

C Gaudy-Marqueste (C)

Aix-Marseille University, APHM, Marseille, France.

A Guminski (A)

Melanoma Institute Australia, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.

J Malvehy (J)

Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain.

N Basset-Seguin (N)

Dermatology Department, Saint-Louis Hospital, Paris, France.

B Bertrand (B)

Plastic, Reconstructive and Aesthetic Surgery Department, La Conception Hospital, Marseille, France.

P Fernandez-Penas (P)

Centre for Translational Skin Research, The University of Sydney, Westmead, NSW, Australia.
Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia.

R Kaufmann (R)

Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt, Germany.

I Zalaudek (I)

Dermatology Clinic, University of Trieste, Trieste, Italy.

M C Fargnoli (MC)

Department of Dermatology, University of L'Aquila, L'Aquila, Italy.

L Tagliaferri (L)

Dipartimento di Scienze Radiologiche, Radioterapiche Ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Rome, Italy.

B Fertil (B)

Anapix Medical, Meyreuil, France.

V Del Marmol (V)

Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

A Stratigos (A)

Department of Dermatology- Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece.

C Garbe (C)

Centre for Dermatooncology, Department of Dermatology, Eberhard-Karls University, Tuebingen, Germany.

K Peris (K)

Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH